CD44 and MMP9 are frequently utilized as immunohistochemical markers that are concurrently evaluated in renal cell carcinoma (RCC) and have been identified as potential molecular prognostic markers for RCC [17]. The gene discussed is MMP9; the disease is hereditary clear cell renal cell carcinoma.